Natera, Inc. - Common Stock (NQ:NTRA)

200.17 -7.87 (-3.78%)

Streaming Delayed Price Updated: 4:00 PM EST, Mar 2, 2026 Add to My Watchlist

Price and Volume

Volume	1,481,167
Open	200.17
Bid (Size)	194.05 (200)
Ask (Size)	200.55 (100)
Prev. Close	208.04
Today's Range	196.22 - 203.91
52wk Range	125.38 - 256.36
Shares Outstanding	139,693,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗

February 28, 2026

The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics.

Via The Motley Fool

Why Natera (NTRA) Shares Are Falling Today

February 27, 2026

Shares of genetic testing company Natera (NASDAQ:NTRA). fell 8.3% in the afternoon session after the release of a key inflation report revealed prices paid to U.S. producers rose more than anticipated...

Via StockStory

Performance

YTD	-12.5%	-12.5%
1 Month	-13.4%	-13.4%
3 Month	-14.5%	-14.5%
6 Month	+18.2%	+18.2%
1 Year	+39.9%	+39.9%

More News

Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

February 27, 2026

From Natera, Inc.

Via Business Wire

Natera (NTRA) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

Via The Motley Fool

Natera Inc. (NASDAQ:NTRA) Crushes Q4 Earnings Estimates with Strong Oncology Growth ↗

February 26, 2026

Via Chartmill

Natera Reports Fourth Quarter and Full Year 2025 Financial Results

February 26, 2026

From Natera, Inc.

Via Business Wire

Natera Earnings: What To Look For From NTRA

February 24, 2026

Via StockStory

Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer

February 24, 2026

From Natera, Inc.

Via Business Wire

Billionaire Stanley Druckenmiller Is Betting Big on These 2 Stocks ↗

February 21, 2026

Via The Motley Fool

Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026

February 17, 2026

From Natera, Inc.

Via Business Wire

Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

February 06, 2026

From Natera, Inc.

Via Business Wire

Natera Submits Signatera™ CDx PMA to FDA

February 02, 2026

From Natera, Inc.

Via Business Wire

Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation

January 28, 2026

From Natera, Inc.

Via Business Wire

Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care

January 26, 2026

From Natera, Inc.

Via Business Wire

2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds

January 25, 2026

Via StockStory

Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

January 21, 2026

From Natera, Inc.

Via Business Wire

Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting

January 20, 2026

From Natera, Inc.

Via Business Wire

GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth

January 13, 2026

Via MarketMinute

Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization

January 13, 2026

Via MarketMinute

Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling

January 13, 2026

From Natera, Inc.

Via Business Wire

Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA

January 12, 2026

From Natera, Inc.

Via Business Wire

Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth

January 11, 2026

From Natera, Inc.

Via Business Wire

2 Cash-Heavy Stocks to Keep an Eye On and 1 We Question

January 10, 2026

Via StockStory

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 07, 2026

Via Chartmill

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

January 07, 2026

From Exelixis, Inc.

Via Business Wire

Frequently Asked Questions

Is Natera, Inc. - Common Stock publicly traded?

Yes, Natera, Inc. - Common Stock is publicly traded.

What exchange does Natera, Inc. - Common Stock trade on?

Natera, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Natera, Inc. - Common Stock?

The ticker symbol for Natera, Inc. - Common Stock is NTRA on the Nasdaq Stock Market

What is the current price of Natera, Inc. - Common Stock?

The current price of Natera, Inc. - Common Stock is 200.17

When was Natera, Inc. - Common Stock last traded?

The last trade of Natera, Inc. - Common Stock was at 03/02/26 04:00 PM ET

What is the market capitalization of Natera, Inc. - Common Stock?

The market capitalization of Natera, Inc. - Common Stock is 27.96B

How many shares of Natera, Inc. - Common Stock are outstanding?

Natera, Inc. - Common Stock has 28B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.